Parkinson's disease (PD) is a progressive neurodegenerative disorder in which the
degeneration of dopaminergic neurons projecting from the substantia nigra to the striatum is …

The clinical trials with intrastriatal transplantation of human fetal mesencephalic tissue, rich
in dopaminergic neurons, in Parkinson's disease (PD) patients show that cell replacement …

Parkinson's disease (PD) is a neurodegenerative disorder, characterised by the progressive
loss of dopaminergic neurons in the substantia nigra, and typically treated by dopamine …

Cell replacement therapy has been proposed as a means of replacing specific populations
of cells lost through trauma, disease or ageing. Parkinson's disease is a progressive …

Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal
pathway which has led to the successful development of drug therapies that replace or …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

Clinical studies with intrastriatal transplants of human embryonic mesencephalic tissue have
provided proof-of-principle for the cell replacement strategy in Parkinson's disease (PD) …

Cell replacement therapy in Parkinson's disease (PD) has so far been based on the use of
primary dopaminergic (DA) neuroblasts obtained from the brain of aborted human fetuses …

The rationale behind the use of cells as therapeutic modalities for neurodegenerative
diseases in general, and in Parkinson's disease (PD) in particular, is that they will improve …

Current approaches to cell replacement therapy in Parkinson's disease are strongly focused
on the dopamine system, with the view that restoring dopaminergic inputs in a localized and …